Literature DB >> 30158057

Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.

Marat Fudim1, Christopher M O'Connor2, Hillary Mulder3, Adrian Coles3, Ankeet S Bhatt4, Andrew P Ambrosy5, William E Kraus6, Ileana L Piña7, David J Whellan8, Robert J Mentz5.   

Abstract

BACKGROUND: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF.
METHODS: HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35% to aerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively.
RESULTS: A total of 2,004 (86%) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak Vo2 in adjusted analyses (all P > .05). A dose increase was associated with decrease in 6-minute walk distance (-4.25 m, SE 1.12 m, P < .001) and change in Kansas City Cardiomyopathy Questionnaire overall score (-0.56 m, SE 0.24 m, P = .02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95% CI 0.72-1.15; P = .432).
CONCLUSIONS: The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health status outcomes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30158057      PMCID: PMC6283675          DOI: 10.1016/j.ahj.2018.06.017

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  20 in total

1.  Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure.

Authors:  Peter K Bonfils; Morten Damgaard; Mustafa Taskiran; Jens Peter Goetze; Peter Norsk; Niels Gadsbøll
Journal:  Eur J Heart Fail       Date:  2010-07-08       Impact factor: 15.534

2.  The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction.

Authors:  Sanjay Gupta; Carolyn Waywell; Nandkumar Gandhi; Nigel Clayton; Brian Keevil; Andrew L Clark; Leong L Ng; Nicholas Brooks; Ludwig Neyses
Journal:  Eur J Heart Fail       Date:  2010-06-04       Impact factor: 15.534

3.  Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model.

Authors:  Christopher M O'Connor; David J Whellan; Daniel Wojdyla; Eric Leifer; Robert M Clare; Stephen J Ellis; Lawrence J Fine; Jerome L Fleg; Faiez Zannad; Steven J Keteyian; Dalane W Kitzman; William E Kraus; David Rendall; Ileana L Piña; Lawton S Cooper; Mona Fiuzat; Kerry L Lee
Journal:  Circ Heart Fail       Date:  2011-11-23       Impact factor: 8.790

4.  Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.

Authors:  C P Green; C B Porter; D R Bresnahan; J A Spertus
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

5.  Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale.

Authors:  David J Whellan; Christopher M O'Connor; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston-Miller; Jerome L Fleg; Kevin A Schulman; Ileana L Piña
Journal:  Am Heart J       Date:  2007-02       Impact factor: 4.749

6.  Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure.

Authors:  Petra Nijst; Frederik H Verbrugge; Philippe B Bertrand; Pieter Martens; Matthias Dupont; Olivier Drieskens; Joris Penders; W H Wilson Tang; Wilfried Mullens
Journal:  J Card Fail       Date:  2016-08-22       Impact factor: 5.712

7.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.

Authors:  Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

8.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

Authors:  Michael Domanski; James Norman; Bertram Pitt; Mark Haigney; Stephen Hanlon; Eliot Peyster
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

9.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.

Authors:  J Bayliss; M Norell; R Canepa-Anson; G Sutton; P Poole-Wilson
Journal:  Br Heart J       Date:  1987-01

10.  Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis.

Authors:  F L Dini; S Ghio; C Klersy; A Rossi; A Simioniuc; L Scelsi; F T Genta; M Cicoira; L Tavazzi; P L Temporelli
Journal:  Int J Clin Pract       Date:  2013-07       Impact factor: 2.503

View more
  1 in total

1.  Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.

Authors:  Alice M Jackson; Pooja Dewan; Inder S Anand; Jan Bělohlávek; Olof Bengtsson; Rudolf A de Boer; Michael Böhm; David W Boulton; Vijay K Chopra; David L DeMets; Kieran F Docherty; Andrej Dukát; Peter J Greasley; Jonathan G Howlett; Silvio E Inzucchi; Tzvetana Katova; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Daniel Lindholm; Charlotta E A Ljungman; Felipe A Martinez; Eileen O'Meara; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; Sergey Tereshchenko; Subodh Verma; Pardeep S Jhund; John J V McMurray
Journal:  Circulation       Date:  2020-07-16       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.